Barclays’s Neumora Therapeutics NMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$50.5K Buy
84,730
+18,504
+28% +$25.6K ﹤0.01% 4572
2026
Q2
$113K Buy
66,226
+31,719
+92% +$60.4K ﹤0.01% 3983
2026
Q1
$67.3K Buy
34,507
+3,583
+12% +$9.28K ﹤0.01% 4193
2025
Q4
$55.4K Buy
30,924
+20,683
+202% +$45.3K ﹤0.01% 4721
2025
Q3
$18.6K Sell
10,241
-2,469
-19% -$3.99K ﹤0.01% 4950
2025
Q2
$9.32K Sell
12,710
-94,025
-88% -$71.2K ﹤0.01% 4921
2025
Q1
$107K Sell
106,735
-60,087
-36% -$103K ﹤0.01% 4383
2024
Q4
$1.77M Buy
166,822
+37,612
+29% +$451K ﹤0.01% 2976
2024
Q3
$1.71M Buy
129,210
+100,678
+353% +$1.17M ﹤0.01% 2980
2024
Q2
$280K Buy
28,532
+18,110
+174% +$187K ﹤0.01% 3380
2024
Q1
$143K Sell
10,422
-10,117
-49% -$164K ﹤0.01% 4286
2023
Q4
$350K Buy
+20,539
New +$252K ﹤0.01% 4108

Other funds holding NMRA

Barclays's NMRA Position: Q3 2026 in Review

Barclays increased its Neumora Therapeutics (NMRA) stake by 28% in Q3 2026, buying an estimated $25.6K and bringing the position to 84,730 shares worth $50.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4572.

Barclays first reported a position in NMRA in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.77M in Q4 2024. 127 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.

  • Barclays held 84,730 shares of Neumora Therapeutics worth $50.5K as of Q3 2026.
  • Barclays bought 18,504 Neumora Therapeutics shares in Q3 2026, an estimated $25.6K.
  • Neumora Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4572 holding.
  • Barclays first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Barclays's Neumora Therapeutics position peaked at $1.77M in Q4 2024.
  • 127 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.